000145148 001__ 145148
000145148 005__ 20240321221031.0
000145148 0247_ $$2doi$$a10.3233/JAD-190819
000145148 0247_ $$2pmid$$apmid:31884468
000145148 0247_ $$2ISSN$$a1387-2877
000145148 0247_ $$2ISSN$$a1875-8908
000145148 0247_ $$2altmetric$$aaltmetric:73652434
000145148 037__ $$aDZNE-2020-00507
000145148 041__ $$aEnglish
000145148 082__ $$a610
000145148 1001_ $$0P:(DE-2719)9001143$$aWohlgemuth, Anne$$b0$$eFirst author$$udzne
000145148 245__ $$aDrug-Related Problems Increase Healthcare Costs for People Living with Dementia.
000145148 260__ $$aAmsterdam$$bIOS Press$$c2020
000145148 264_1 $$2Crossref$$3print$$bIOS Press$$c2020-01-21
000145148 3367_ $$2DRIVER$$aarticle
000145148 3367_ $$2DataCite$$aOutput Types/Journal article
000145148 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1710934255_2065
000145148 3367_ $$2BibTeX$$aARTICLE
000145148 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000145148 3367_ $$00$$2EndNote$$aJournal Article
000145148 520__ $$aDrug-related problems (DRP) are common in the elderly population, especially in people living with dementia (PwD). DRP are associated with adverse outcomes that could result in increased costs.The objective of the study was to analyze the association between DRP and healthcare costs in PwD.The analysis was based on the cross-sectional data of 424 PwD. Compliance, adverse effects, and drug administration of prescribed and over-the-counter drugs taken were assessed. DRP were identified and classified by pharmacists using an adapted German version of 'PIE-Doc®'. Healthcare utilization was assessed retrospectively used to calculated costs from a public payer perspective using standardized unit costs. The associations between DRP and healthcare costs were analyzed using multiple linear regression models.394 PwD (93%) had at least one DRP. An inappropriate drug choice was significantly associated with increased total costs (b = 2,718€; CI95% 1,448-3,988) due to significantly higher costs for hospitalization (b = 1,936€; 670-3,202) and for medications (b = 417€; 68-765). Problems with medication dosage and drug interactions were significantly associated with higher medication costs (b = 679€; 31-1,328; and b = 630€; 259-1,001, respectively).DRP could significantly lead to adverse outcomes for PwD and healthcare payers, reflected by a higher hospitalization and costs, respectively. Further research is needed to clarify on interventions and approaches efficiently avoiding DRP and on the effect on patient-reported and economic outcomes.
000145148 536__ $$0G:(DE-HGF)POF3-344$$a344 - Clinical and Health Care Research (POF3-344)$$cPOF3-344$$fPOF III$$x0
000145148 588__ $$aDataset connected to CrossRef, PubMed,
000145148 650_2 $$2MeSH$$aAged
000145148 650_2 $$2MeSH$$aAged, 80 and over
000145148 650_2 $$2MeSH$$aCross-Sectional Studies
000145148 650_2 $$2MeSH$$aDementia: economics
000145148 650_2 $$2MeSH$$aDrug Interactions
000145148 650_2 $$2MeSH$$aDrug-Related Side Effects and Adverse Reactions: economics
000145148 650_2 $$2MeSH$$aDrug-Related Side Effects and Adverse Reactions: epidemiology
000145148 650_2 $$2MeSH$$aFemale
000145148 650_2 $$2MeSH$$aGermany: epidemiology
000145148 650_2 $$2MeSH$$aHealth Care Costs: statistics & numerical data
000145148 650_2 $$2MeSH$$aHumans
000145148 650_2 $$2MeSH$$aMale
000145148 650_2 $$2MeSH$$aNonprescription Drugs
000145148 650_2 $$2MeSH$$aPatient Acceptance of Health Care
000145148 650_2 $$2MeSH$$aPatient Compliance
000145148 650_2 $$2MeSH$$aPharmacists
000145148 650_2 $$2MeSH$$aPrescription Drugs
000145148 650_2 $$2MeSH$$aRetrospective Studies
000145148 650_2 $$2MeSH$$aSocioeconomic Factors
000145148 7001_ $$0P:(DE-2719)2810763$$aMichalowsky, Bernhard$$b1$$udzne
000145148 7001_ $$0P:(DE-2719)2810631$$aWucherer, Diana$$b2$$udzne
000145148 7001_ $$0P:(DE-2719)2810514$$aEichler, Tilly$$b3$$udzne
000145148 7001_ $$0P:(DE-2719)2290613$$aThyrian, Jochen René$$b4$$udzne
000145148 7001_ $$0P:(DE-2719)2811869$$aZwingmann, Ina$$b5$$udzne
000145148 7001_ $$0P:(DE-2719)9001134$$aRädke, Anika$$b6$$udzne
000145148 7001_ $$0P:(DE-2719)2000040$$aHoffmann, Wolfgang$$b7$$eLast author$$udzne
000145148 77318 $$2Crossref$$3journal-article$$a10.3233/jad-190819$$b : IOS Press, 2020-01-21$$n2$$p791-799$$tJournal of Alzheimer's Disease$$v73$$x1387-2877$$y2020
000145148 773__ $$0PERI:(DE-600)2070772-1$$a10.3233/JAD-190819$$gVol. 73, no. 2, p. 791 - 799$$n2$$p791-799$$tJournal of Alzheimer's disease$$v73$$x1387-2877$$y2020
000145148 8564_ $$uhttps://pub.dzne.de/record/145148/files/DZNE-2020-00507_Restricted.pdf
000145148 8564_ $$uhttps://pub.dzne.de/record/145148/files/DZNE-2020-00507_Restricted.pdf?subformat=pdfa$$xpdfa
000145148 909CO $$ooai:pub.dzne.de:145148$$pVDB
000145148 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001143$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000145148 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810763$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000145148 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810631$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000145148 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810514$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000145148 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2290613$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000145148 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811869$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000145148 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001134$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000145148 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000040$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000145148 9131_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x0
000145148 9141_ $$y2020
000145148 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-06
000145148 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-01-06
000145148 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-18
000145148 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-18
000145148 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-18
000145148 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-18
000145148 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-18
000145148 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ ALZHEIMERS DIS : 2021$$d2022-11-18
000145148 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-18
000145148 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-18
000145148 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-18
000145148 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-18
000145148 9201_ $$0I:(DE-2719)5000067$$kAG Michalowsky ; AG Michalowsky$$lPatient-Reported Outcomes and Health Economics Research$$x0
000145148 9201_ $$0I:(DE-2719)5000001$$kAG Grabe$$lBiomarkers of Dementia in the General Population$$x1
000145148 9201_ $$0I:(DE-2719)1510800$$kAG Thyrian$$lInterventional Health Care Research (IHCR)$$x2
000145148 9201_ $$0I:(DE-2719)1510600$$kAG Hoffmann$$lTranslational Health Care Research$$x3
000145148 980__ $$ajournal
000145148 980__ $$aVDB
000145148 980__ $$aI:(DE-2719)5000067
000145148 980__ $$aI:(DE-2719)5000001
000145148 980__ $$aI:(DE-2719)1510800
000145148 980__ $$aI:(DE-2719)1510600
000145148 980__ $$aUNRESTRICTED
000145148 999C5 $$2Crossref$$oPrince World Alzheimer Report 2016. Improving healthcare for people living with dementia: Coverage, quality and costs now and in the future 2016$$tWorld Alzheimer Report 2016. Improving healthcare for people living with dementia: Coverage, quality and costs now and in the future$$y2016
000145148 999C5 $$2Crossref$$oPrince World Alzheimer Report 2015. The global impact of dementia: An analysis of prevalence, incidence, cost and trends 2015$$tWorld Alzheimer Report 2015. The global impact of dementia: An analysis of prevalence, incidence, cost and trends$$y2015
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1038/srep42084$$o10.1038/srep42084
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/S0140-6736(17)33185-9$$o10.1016/S0140-6736(17)33185-9
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/S0140-6736(05)67889-0$$o10.1016/S0140-6736(05)67889-0
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1136/jnnp.74.9.1206$$o10.1136/jnnp.74.9.1206
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1111/j.1532-5415.2005.00543.x$$o10.1111/j.1532-5415.2005.00543.x
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1186/1471-244X-11-190$$o10.1186/1471-244X-11-190
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1111/j.1365-2125.2006.02744.x$$o10.1111/j.1365-2125.2006.02744.x
000145148 999C5 $$2Crossref$$oSell Identification of drug-related problems by means of pharmacy-based medication review – results of a project to optimise medication safety 2017$$tIdentification of drug-related problems by means of pharmacy-based medication review – results of a project to optimise medication safety$$y2017
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1023/A:1019543029936$$o10.1023/A:1019543029936
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1186/s40360-017-0157-2$$o10.1186/s40360-017-0157-2
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.archger.2011.02.005$$o10.1016/j.archger.2011.02.005
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1007/s40801-016-0061-x$$o10.1007/s40801-016-0061-x
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/gps.3806$$o10.1002/gps.3806
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1080/13814788.2017.1288211$$o10.1080/13814788.2017.1288211
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/S1543-5946(04)90015-3$$o10.1016/S1543-5946(04)90015-3
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1111/j.1365-2125.2009.03419.x$$o10.1111/j.1365-2125.2009.03419.x
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1017/S1041610217001442$$o10.1017/S1041610217001442
000145148 999C5 $$2Crossref$$oLyra
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1007/s00228-016-2084-3$$o10.1007/s00228-016-2084-3
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1371/journal.pone.0146811$$o10.1371/journal.pone.0146811
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1001/archinte.1997.00440390083011$$o10.1001/archinte.1997.00440390083011
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1186/1745-6215-13-56$$o10.1186/1745-6215-13-56
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/gps.1042$$o10.1002/gps.1042
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1136/ebmh.7.3.70$$o10.1136/ebmh.7.3.70
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.3233/JAD-151076$$o10.3233/JAD-151076
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/0022-3956(75)90026-6$$o10.1016/0022-3956(75)90026-6
000145148 999C5 $$2Crossref$$oCreavin 2016$$y2016
000145148 999C5 $$2Crossref$$oDeuschl Deutsche Gesellschaft für Neurologie, Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie 2016$$tDeutsche Gesellschaft für Neurologie, Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie$$y2016
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/0022-3956(82)90033-4$$o10.1016/0022-3956(82)90033-4
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/0021-9681(87)90171-8$$o10.1016/0021-9681(87)90171-8
000145148 999C5 $$2Crossref$$oBock 2015$$y2015
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1007/s10198-017-0869-7$$o10.1007/s10198-017-0869-7
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1186/1471-2318-13-121$$o10.1186/1471-2318-13-121
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1186/s12877-018-0704-8$$o10.1186/s12877-018-0704-8
000145148 999C5 $$2Crossref$$oHolt 2010$$y2010
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.2147/CIA.S159966$$o10.2147/CIA.S159966
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1007/s11096-014-0063-2$$o10.1007/s11096-014-0063-2
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.3111/13696998.2015.1014090$$o10.3111/13696998.2015.1014090
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1080/17843286.2017.1410606$$o10.1080/17843286.2017.1410606
000145148 999C5 $$2Crossref$$o
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1186/s12913-016-1366-x$$o10.1186/s12913-016-1366-x
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.pharma.2008.11.003$$o10.1016/j.pharma.2008.11.003
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1248/yakushi.15-00109$$o10.1248/yakushi.15-00109
000145148 999C5 $$2Crossref$$oParker 2008$$y2008
000145148 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1007/s40266-017-0505-3$$o10.1007/s40266-017-0505-3
000145148 999C5 $$2Crossref$$oReilly 2015$$y2015